STK1p As a Prognostic Biomarker for Overall Survival in non-small-cell Lung carcinoma, Based on real-world Data

References

• SiegelRL , MillerKD , JemalA. Cancer statistics 2019. CA Cancer J. Clin.69, 7–34 (2019).
   PubMed Web of Science ®Google Scholar
• BrayF , FerlayJ , SoerjomataramIet al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• TestaU , CastelliG , PelosiE. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel).10(8), 248 (2018).
   PubMed Web of Science ®Google Scholar
• CrosbiePA , ShahR , SummersY , DiveC , BlackhallF. Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Transl. Lung Cancer Res.2, 2382–2397 (2013).
   Google Scholar
• YangQ , ZhangP , WuR , LuK , ZhouH. Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible?Dis. Markers1, 1–12 (2018).
   Google Scholar
• JiangZF , WangM , XuJL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci.194, 1–6 (2018).
   PubMed Web of Science ®Google Scholar
• WuJT. Circulating Tumor Markers of the New Millennium 584.AACC Press, NY, USA, 115–117 (2002).
   Google Scholar
• WangY , JiangX , DongSet al.Serum TK1 is a more reliable marker than CEA and AFP for cancer screening survey in a study of 56,286 people. Cancer Biomark.11, 529–536 (2016).
   Google Scholar
• WangY , JiangX , WangSet al.Serological TK1 predict pre-cancer in routine health screenings of 56,178 people. Cancer Biomark.22, 237–247 (2018).
   PubMed Web of Science ®Google Scholar
• WeagelEG , BurrupW , KovtunRet al.Correction to: membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies. Cancer Cell Int.19, 29 (2019).
   PubMed Web of Science ®Google Scholar
• Cleaver. Thymidine metabolism and cell kinetics. NeubergerA, TatumEL ( Eds). Frontiers of Biology.North-Holland Publishing, Amsterdam, 43–125 (1967).
   Google Scholar
• SherleyJL , KellyTJ. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem.263, 8350–8358 (1988).
   PubMed Web of Science ®Google Scholar
• KauffmanMG , KellyTJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol. Cell. Biol.11, 2538–2546 (1991).
   PubMed Web of Science ®Google Scholar
• HeQ , SkogS , WangN , ErikssonS , TribukaitB. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur. J. Cell Biol.70, 117–124 (1996).
   PubMed Web of Science ®Google Scholar
• WeagelEG , BurrupW , KovtunRet al.Correction to: membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies. Cancer Cell Int.19, 29 (2019).
   PubMed Web of Science ®Google Scholar
• HeE , HaghdoostS. Prevention and Early Detection of Human Tumour. SkogS ( Ed.). Lambert Academic Publishing, Schaltungsdienst Lange O.H.G., Berlin, 183–257 (2017). http://www. morebooks.de
   Google Scholar
• GronowitzJS , HagbergH , KällanderCF , SimonssonB. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin’s lymphoma. Br. J. Cancer47, 487–495 (1983).
   PubMed Web of Science ®Google Scholar
• TopolcanO , LubosHolubec L. The role of thymidine kinase in cancer diseases. Expert Opin. Med. Diagn.2, 129–140 (2008).
   PubMedGoogle Scholar
• ChenY , YingM , ChenYet al.Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int. J. Clin. Oncol.15(4), 359–368 (2010).
   PubMed Web of Science ®Google Scholar
• ZhouJ , HeE , SkogS. The proliferation marker thymidine kinase 1 in clinical use. Mol. Clin. Oncol.1, 18–28 (2013).
   PubMedGoogle Scholar
• JagarlamudiKK , ShawM. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark. Med.12, 1035–1048 (2018).
   PubMed Web of Science ®Google Scholar
• HeQ , FornanderT , JohanssonHet al.Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res.26(6C), 4753–4759 (2006).
   PubMed Web of Science ®Google Scholar
• PanZ , JiX , ShiY , ZhouJ , HeE , SkogS. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J. Cancer Res. Clin. Oncol.136(8), 1193–1199 (2010).
   PubMed Web of Science ®Google Scholar
• ChenF , TangL , XiaTet al.Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol. Clin. Oncol.1(5), 894–902 (2013).
   PubMedGoogle Scholar
• LouX , ZhouJ , MaHet al.The half-life of serum thymidine kinase 1 concentration is an important tool for monitoring surgical response in patients with lung cancer: a meta-analysis. Genet. Test. Mol. Biomarkers21(8), 471–478 (2017).
   PubMed Web of Science ®Google Scholar
• ChenZH , HuangSQ , WangYet al.Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors11(12), 11064–11080 (2011).
   PubMed Web of Science ®Google Scholar
• CaoX , WangYO , YangPT , ZhouH , LiuC , ChenZH. Application of serum thymidine1 of 26,055 cases in health screening for early detection of premalignant/early malignant tumours. J. Central South University China (Medicine)39(10), 1029–1033 (2014).
   Google Scholar
• ChenZH , WangY , ChenGet al.Chapter 21. Serum-biomarker thymidine kinase 1 for early discovery of tumour process of 160,086 participants using a sensitive immune-ECL-dot-blot detection system. In: Advances in Sensors: Reviews, Volume 6.YurishSY ( Ed.). International Frequency Sensor Association Publishing, Barcelona, Spain, 529–540 (2018). http://www.sensorsportal.com
   Google Scholar
• NismanB , NechushtanH , BiranHet al.Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. Thorac. Oncol.9, 1568–1572 (2014).
   PubMed Web of Science ®Google Scholar
• KaplanNM , SproulLE , MulcahyWS. Large prospective study of ramipril in patients with hypertension CARE investigators. J. Clin. Ther.15(5), 810–818 (1993).
   PubMed Web of Science ®Google Scholar
• ShermanRE , AndersonSA , DalPan GJet al.Real-world evidence – what is it and what can it tell us?N. Engl. J. Med.375(23), 2293–2297 (2016).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff [EB/OL]. ( Document issued on 31 August 2017). http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM513027.pdf.2016
   Google Scholar
• TribukaitB. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume. BMC Cancer20(1), 440 (2020).
   PubMed Web of Science ®Google Scholar
• LiZ , WangY , HeJet al.Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur. J. Cancer Prev.19(4), 313–318 (2010).
   PubMed Web of Science ®Google Scholar
• GakisG , HennenlotterJ , ScharpfMet al.XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J. Urol.29(6), 801–806 (2011).
   PubMed Web of Science ®Google Scholar
• GaronEB , RizviNA , HuiRet al.Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med.21, 2018–2028 (2015).
   Google Scholar
• NinomiyaK , HottaK. Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin. Biol. Ther.18(10), 1015–1021 (2018).
   PubMed Web of Science ®Google Scholar
• ShenK , CuiJ , WeiYet al.Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: a meta-analysis. J. Thorac. Dis.10, 6636–6652 (2018).
   PubMed Web of Science ®Google Scholar
• DenekaAY , BoumberY , BeckT , GolemisEA. Tumor-targeted drug conjugates as an emerging novel therapeutic approach in small cell lung cancer (SCLC). Cancers (Basel)11(9), 1297 (2019).
   PubMed Web of Science ®Google Scholar